SCHEMBL825844

SCHEMBL825844

COc1cc(NC(=O)c2ccccc2)c(OC)cc1C

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.76
KMT2A Q03164 5/20 0.76
SMN1; SMN2 Q16637 2/20 0.70
MAPK1 P28482 2/20 0.70
MAPT P10636 2/20 0.70
AHR P35869 1/20 0.70
ALDH1A1 P00352 3/20 0.68
KDM4E B2RXH2 2/20 0.63
HSD17B10 Q99714 1/20 0.63
HDAC1 Q13547 1/20 0.62
HDAC8 Q9BY41 1/20 0.62
HDAC6 Q9UBN7 1/20 0.62
POLB P06746 1/20 0.58
THRB P10828 1/20 0.58
RECQL P46063 1/20 0.58
BLM P54132 1/20 0.58
CTDSP1 Q9GZU7 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
HTT P42858 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16231124 0.92 MEN1 (0.73) MEN1KMT2ASMN1; SMN2MAPK1MAPT
SCHEMBL9196352 0.90 MEN1 (0.67) MEN1KMT2ASMN1; SMN2MAPK1MAPT
SCHEMBL9192693 0.88 MEN1 (0.68) MEN1KMT2ASMN1; SMN2MAPK1MAPT
SCHEMBL10647491 0.87 MEN1 (0.62) MEN1KMT2ASMN1; SMN2MAPK1MAPT
SCHEMBL13788777 0.86 MEN1 (0.78) MEN1KMT2ASMN1; SMN2MAPK1MAPT
SCHEMBL5475142 0.84 MEN1 (0.66) MEN1KMT2ASMN1; SMN2MAPK1MAPT
SCHEMBL27626674 0.84 MEN1 (0.58) MEN1KMT2ASMN1; SMN2MAPK1MAPT
SCHEMBL13788794 0.84 MEN1 (0.66) MEN1KMT2ASMN1; SMN2MAPK1MAPT
SCHEMBL14178770 0.84 MEN1 (0.63) MEN1KMT2ASMN1; SMN2MAPK1MAPT
SCHEMBL592866 0.84 MEN1 (0.74) MEN1KMT2ASMN1; SMN2MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210088518-A1 DETECTING MICROBIAL INFECTION IN WOUNDS SYNOVO GMBH (DE) 2021-03-25 US disclosed
EP-2588144-B1 DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY VENTANA MED SYST INC (US) 2018-05-09 EP disclosed
US-9791399-B2 Derivatization of carbon SCHLUMBERGER TECHNOLOGY CORPORATION (US) 2017-10-17 US disclosed
US-9291597-B2 Detecting targets using mass tags and mass spectrometry VENTANA MEDICAL SYSTEMS, INC. (US) 2016-03-22 US disclosed
US-20140332412-A1 DERIVATIZATION OF CARBON SCHLUMBERGER TECHNOLOGY COPORATION (US) 2014-11-13 US disclosed
US-20130122516-A1 DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY VENTANA MEDICAL SYSTEMS, INC. 2013-05-16 US disclosed
WO-2012003478-A2 DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY VENTANA MEDICAL SYSTEMS, INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140332412-A1 DERIVATIZATION OF CARBON FTH1, CBR1, SDHB MEN1 1759/4885KMT2A 961/4885SMN1; SMN2 4435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.